IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#3705
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$1.4B
Arthur T. Sands
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies. NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy, is in Phase 1 clinical trials for gynecologic cancers, including ovarian, endometrial, and cervical cancer.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$NRIX Nurix Therapeutics, Inc. | 39 | 42 | 14 | 55 | - | - | -43.7% | -34.2% | 100.0% | -510.5% | -471.9% | -34.7% | 0.0% | 28.0x | $1.4B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
Nurix Therapeutics, Inc. (NRIX) receives a "Avoid" rating with a composite score of 38.7/100. It ranks #3705 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Arthur T. Sands
Chief Executive Officer
Labor Force
300
42
23
47
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for NRIX
In-line with peers — no strong momentum signal
Expensive relative to fundamentals — limited margin of safety
Average quality profile
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for NRIX.
View All RatingsMaterial decline in asset turnover efficiency detected
High margin volatility — erratic forensic earnings quality
ROE proxy -43.7% (sector -2.5%)
GM 100% vs sector 43%, OM -510% vs sector 1%
Capital turnover N/A, R&D intensity 377.4%
Rev growth -35%, 6yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags Nurix Therapeutics, Inc. with an Avoid rating, assigning a composite score of 38.7/100 and 1 out of 5 stars. Ranked #3705 of 7,333 stocks, NRIX falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
NRIX's quality score of 42/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -43.7% (sector avg: -2.5%), gross margins of 100.0% (sector avg: 42.5%), net margins of -471.9% (sector avg: -0.2%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
NRIX registers a value score of just 14/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 3.01x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
Nurix Therapeutics, Inc.'s investment score of 23/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of -34.7% vs. a sector average of 5.9% and a return on assets of -34.2% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
NRIX demonstrates moderate momentum with a score of 55/100, suggesting a neutral price trend without strong directional conviction. Revenue growth stands at -34.7% year-over-year, while a beta of 1.26 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
With a stability score of 47/100, NRIX exhibits average financial resilience. Key stability metrics include a beta of 1.26 and a debt-to-equity ratio of 28.00x (sector avg: 0.2x). While the balance sheet is not a major concern, the stock is subject to typical market volatility and may experience sharper drawdowns during risk-off episodes.
Nurix Therapeutics, Inc.'s short interest score of 27/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include above-average market sensitivity (beta: 1.26), elevated leverage (D/E: 28.00x), small-cap liquidity risk. At $1.4B (small-cap), NRIX carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
Nurix Therapeutics, Inc. is a small-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #3705 of 7,333 overall (49th percentile). Key comparisons include ROE of -43.7% trailing the -2.5% sector median and operating margins of -510.5% below the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While NRIX currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Value (14) would have the largest impact on the composite score.
ROE 1660% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 135% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 39670% BELOW SECTOR MEDIAN
AUDIT DATA AS OF AUG 31, 2025 (Q2 FY2025)
We rate Nurix Therapeutics, Inc. (NRIX) as Avoid with a composite score of 38.7/100 at a current price of $16.02. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in momentum (55th percentile) and stability (47th percentile), which together account for the majority of the composite score. Offsetting weakness in value (14th percentile) and investment (23th percentile) tempers our overall conviction. We assign a No Moat rating (33/100), High uncertainty, and Poor capital allocation.
Key items to watch: the path to profitability; valuation compression risk if growth disappoints. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
Nurix Therapeutics, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 38.7/100 places it at rank #3705 in our full 7,333-stock universe. At $1.4B in market capitalization, Nurix Therapeutics, Inc. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue contraction of -35% combined with momentum at the 55th percentile paints a cautious picture of the near-term business outlook. The market appears to be pricing in continued challenges, and a catalyst for reversal is not clearly visible from current data.
The margin cascade tells an important story: gross margins of 100% (+57.5pp vs sector) narrow to operating margins of -510% (-511.7pp vs sector) and net margins of -471.9%, yielding a gross-to-net conversion rate of -472%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $16.02, Nurix Therapeutics, Inc. is trading at a premium to fundamental value. Our value factor score of 14/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at P/B of 3.0x, P/S of 19.6x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
Gross margins of 100% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
A conservative balance sheet (28% D/E) provides financial flexibility for acquisitions, buybacks, or weathering economic downturns without dilution.
The Avoid rating (composite 38.7/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Revenue decline of -35% signals business deterioration — declining revenues make it difficult to grow into the current valuation and often precede further negative revisions.
Thin net margins of -471.9% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
We assign a High uncertainty rating to Nurix Therapeutics, Inc.. Key risk factors include current negative profitability (net margin -471.9%). The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: current negative profitability (net margin -471.9%). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 47th percentile and quality factor at the 42th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 100% provide a buffer against cost pressures; conservative leverage (28% D/E) limits balance sheet risk. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate Nurix Therapeutics, Inc.'s capital allocation as Poor. Key concerns include low returns on equity (-43.7%), negative profitability, weak asset returns (ROA -34.2%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — Nurix Therapeutics, Inc. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, Nurix Therapeutics, Inc. receives a Avoid rating with a composite score of 38.7/100 (rank #3705 of 7,333). Our quantitative framework assigns a No Moat (33/100, trend: stable), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 36/100.
Our analysis does not support a constructive view on Nurix Therapeutics, Inc. at this time. The combination of limited competitive advantages, high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign Nurix Therapeutics, Inc. a meaningful economic moat, scoring 33/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, margin superiority, reached only 12.9/20.
The strongest moat sources are margin superiority (12.9/20) and reinvestment efficiency (7/20). GM 100% vs sector 43%, OM -510% vs sector 1%. Capital turnover N/A, R&D intensity 377.4%. These pillars form the core of Nurix Therapeutics, Inc.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include economic value creation (2.5/20) and growth durability (4.7/20). ROE proxy -43.7% (sector -2.5%). Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect Nurix Therapeutics, Inc.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 100% providing a solid profitability foundation, declining revenues (-35%) that pressure the earnings outlook. The margin cascade from 100% gross to -510% operating to -471.9% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality is adequate though not exceptional, with the quality factor at the 42th percentile.
The margin profile shows gross margins of 100%, operating margins of -510%, net margins of -471.9%. Return metrics include ROE of -43.7% and ROA of -34.2%. Relative to the Manufacturing sector, gross margins are 57.5 percentage points above the sector median of 43%, and ROE of -43.7% compares to a sector median of -2.5%.
The balance sheet reflects a conservatively managed balance sheet with D/E of 28%, revenue growth of -35%. The sector median D/E is 0%, putting Nurix Therapeutics, Inc. at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
Above 50MA
37.18%
Net New Highs
+51081
Nurix Therapeutics (NRIX) is in focus after reporting full year 2025 earnings that paired revenue of US$83.98 million with a wider net loss of US$264.46 million, alongside a new US$98.8 million shelf registration. See our latest analysis for Nurix Therapeutics. The latest earnings release and shelf registration have arrived after a volatile stretch, with a 31.03% 90 day share price return contrasting with a 12.69% 30 day decline and a 6.44% 1 year total shareholder return fall. This suggests...
Redmile Group increased its stake in Nurix Therapeutics by 4.4 million shares worth $63.43 million, bringing its total position to 11.31% of its assets. Despite the stock being down 6.5% over the past year, the fund's conviction in the biotech company reflects confidence in its lead BTK degrader program entering a registrational trial with strong Phase 1 data showing 83% objective response rate.
This clinical-stage biotech develops antibody therapies for cancer and infectious diseases, leveraging proprietary discovery platforms.
In late January 2026, Nurix Therapeutics reported full-year 2025 revenue of US$83.98 million, up from US$54.55 million, alongside a wider net loss of US$264.46 million and an Employee Stock Ownership Plan-related shelf registration for up to 5,090,373 common shares worth about US$98.80 million. The results came as Nurix advanced its lead BTK degrader bexobrutideg into pivotal DAYBREAK development with Orphan Drug and Fast Track status, backed by partnerships with Gilead, Sanofi, and Pfizer...
We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Nurix Therapeutics, Inc. is placed second on our list. TheFly reported on January 29 that Stifel raised the price target on NRIX to $35 from $33 and maintained a Buy rating. The firm noted that 2026 will be a […]